Clinical Trials Logo

Hepatocellular Carcinoma clinical trials

View clinical trials related to Hepatocellular Carcinoma.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03794440 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.

Start date: January 2019
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of the study is to assess the safety, tolerability and effectiveness of Sintilimab in combination with IBI305 in patients with HCC as the first-line treatment compared with Sorafenib. This study is a randomised, Open-label´╝îMulti-center Study. The primary endpoint is overall survival.

NCT ID: NCT03793725 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

A Trial of SHR-1210 in Combination With Apatinib in Patients With Unresectable HCC

HZ-T-PD1-APA
Start date: January 30, 2019
Phase: Phase 2
Study type: Interventional

This is a Phase II , Open-label , Investigator-initiated Trail of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With unresectable Hepatocellular Carcinoma. This study aims to evaluate the safety and efficacy of SHR-1210 combination with Apatinib as a preoperative treatment of unresectable HCC.

NCT ID: NCT03783871 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

NeuWave HCC China Study

NW
Start date: December 24, 2018
Phase: N/A
Study type: Interventional

This is a single-arm, prospective, multicenter, study. Individuals who are assessed for microwave (MW) ablation of HCC in accordance with their institution's standard of care (SOC), who meet study entry criteria and sign the informed consent, will be enrolled. The subjects will be treated with MW ablation and afterwards followed for up to 36 months after the ablation procedure to assess efficacy and safety. In addition to the final analysis after all enrolled subjects complete the 36-month observation period, a summary of selected endpoints will be provided after all enrolled patients have completed each of the 1-month and 12-month visits. To provide sites with an opportunity to get equal experience in the use of the Certus system, there will 3 patients treated as part of a run-in phase. These patients will only be included in the safety set.

NCT ID: NCT03781960 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma

Start date: January 2019
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to evaluate the effectiveness of the combination of nivolumab and abemaciclib for the treatment of hepatocellular carcinoma. Other goals of this study are to learn about the side effects that this combination of drugs may cause and to learn more about how these drugs work by studying blood and tissue.

NCT ID: NCT03754192 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Perfusion and Dual Energy Computer Tomography in Hepatocellular Carcinoma

PERCAHEC
Start date: December 30, 2018
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the hepatic perfusion computer tomography and dual energy computer tomography in the assessment of tumor characterization of Hepatocellular carcinoma in patients with resectable Hepatocellular carcinoma by comparing the quantitative parameters computer tomography obtained with the pathological data of the surgical specimens.

NCT ID: NCT03752398 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

DUET-3
Start date: February 2019
Phase: Phase 1
Study type: Interventional

This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb23104 in subjects with selected advanced solid tumors.

NCT ID: NCT03748927 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Natural History Study of Children and Adults With Fibrolamellar Hepatocellular Carcinoma

Start date: January 18, 2019
Phase:
Study type: Observational

Background: Fibrolamellar Hepatocellular Carcinoma (FL-HCC) is a rare liver cancer. It usually occurs in young people who have no history of liver disease. Currently the only effective treatment option is surgery that removes the tumor and part of the liver. Researchers want to study the course of the disease to learn more about it. Objective: To collect samples from people with FL-HCC to learn more about the disease and help develop new treatments. Eligibility: People any age with FL-HCC Design: Participants must be enrolled on another NIH protocol. Participants will have at least 1 study visit. They will have: - A medical and cancer history - A physical exam - A review of their symptoms and their ability to do normal activities - Tests to produce images of the body. They may have a scan (CT) that uses a small amount of radiation. Or they may have a scan (MRI) that uses a magnetic field. These will examine the chest, abdomen, and pelvis. - Blood tests Researchers will study previous tumor samples if they are available. If participants come to NIH for visits on other studies, data will be collected about their disease, tests, treatments, and responses. Tumor tissue will be collected if participants are having it taken for a procedure. All other participants will be contacted to collect this data. They will be contacted once a month for 1 year and 2 times a year after that. Participants will be asked to contact researchers when their health changes. They may come in for more tests.

NCT ID: NCT03744247 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC

Start date: January 21, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of lenvatinib combined with PD-1 antibody compared with lenvtinib Alone in patients with advanced hepatocellular carcinoma (HCC)

NCT ID: NCT03738111 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Study of TG02 Citrate in Patients With Advanced Hepatocellular Carcinoma

Start date: December 2018
Phase: Phase 1
Study type: Interventional

This is a single-centre, open-label, dose escalation, Phase 1 study. The primary objective is to determine the highest dose of TG02 citrate that can safely be given to patients with advanced hepatocellular carcinoma.

NCT ID: NCT03734926 Not yet recruiting - Colorectal Cancer Clinical Trials

A Phase 1 Study of ZSP1241 in Participants With Advanced Solid Tumors

Start date: November 20, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics, and determine the maximum tolerated dose of ZSP1241 in participants with hepatocellular carcinoma, cholangiocarcinoma, gastric cancer, esophageal cancer, colorectal cancer and other advanced solid tumors.